(NewsDirect)
Emyria Ltd (ASX:EMD) MD Michael Winlo speaks with Proactive afterthe company received Human Research Ethics Committee (HREC) approvalto conduct its ground-breaking MDMA-assisted clinical therapy forpatients with Post-Traumatic Stress Disorder (PTSD). The trial, knownas EMDMA-001, will be a 12-month, open-label study conducted inpartnership with PAX Centre, one of Australia’s leadingtrauma-focused, multi-disciplinary psychiatric services specialisingin the treatment of complex trauma.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.